Pulsenmore Ltd.
PLSM- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0002064764
In the last 90 days, Pulsenmore Ltd. insiders filed 1 open-market purchase and 0 sales; 3 institutions reported holding it in 13F filings for Q2 2026, worth $2.07M in total; no superinvestor holds it.
- Currency
- ILS
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 3:21 PM ET
Amounts are in ILS, the currency Pulsenmore Ltd. reports in. Lines marked ≈ US$ convert key figures to US dollars.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 |
|---|---|
| Period end | Dec 31, 2025 |
| Filing | 20-F |
| Reported | – |
| Revenue | ILS 40.0M |
| Cost of revenue | ILS 6.34M |
| Gross profit | ILS 33.7M |
| Operating expenses | ILS 12.2M |
| Research and development | ILS 17.4M |
| Selling, general and administrative | ILS 16.7M |
| Interest expense | ILS 7.22M |
| Income tax | ILS 1.00K |
| Net income | ILS -15.9M |
| EPS, basic | ILS 2.46 |
| EPS, diluted | ILS 2.46 |
| Weighted shares, basic | 6.44M |
| Margins and growth | |
| Gross margin | 84.2% |
| Net margin | -39.6% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 |
|---|---|
| Period end | Dec 31, 2025 |
| Filing | 20-F |
| Reported | – |
| Cash and equivalents | ILS 21.6M |
| Inventory | ILS 19.9M |
| Total current assets | ILS 81.4M |
| Property, plant and equipment | ILS 5.82M |
| Total assets | ILS 101.8M |
| Accounts payable | ILS 1.98M |
| Total current liabilities | ILS 10.3M |
| Total liabilities | ILS 18.8M |
| Shareholders' equity | ILS 83.1M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 |
|---|---|
| Period end | Dec 31, 2025 |
| Filing | 20-F |
| Reported | – |
| Operating cash flow | ILS -32.9M |
| Capital expenditures | ILS 135.0K |
| Free cash flow | ILS -33.0M |
| Depreciation and amortization | ILS 2.80M |
| Stock-based compensation | ILS 667.0K |
| Investing cash flow | ILS 13.8M |
| Financing cash flow | ILS 4.00K |
| Net change in cash | ILS -19.0M |
| Ratio | |
| Stock-based compensation, % of revenue | 1.7% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Mar 15, 2026 | 6.50M | – | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- Exchange rates for ILS aren't loaded, so amounts are shown in ILS only.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.